Comparison tool

Crystagen vs Chonluten side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

CrystagenChonluten

Share this peptide comparison

Property	Crystagen	Chonluten
Category	Bioregulators	Bioregulators
Also known as	Glu-Asp-Pro, EDP	Glu-Asp-Gly, EDG
FDA approved	No	No
Clinical status	Preclinical research; reported as supplement-approved in Russia Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical research; reported supplement approval in Russia; not FDA or EMA approved Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Immune system, spleen health, immune aging	Respiratory health, lung function, bronchial support
How it works	Crystagen is presented as a cytogen-class short peptide. In the supplied source, the Khavinson group hypothesizes that EDP can influence lymphocyte proliferation and differentiation and may reactivate chromatin in aged immune cells, potentially relating to T-cell function through tissue-specific gene-expression regulation. The source explicitly treats this as a proposed epigenetic model supported by that group's in vitro work, not as independent scientific consensus.	Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.
Typical dosing	10-20 mg daily · Once or twice daily	10-20 mg daily · Once or twice daily
Research dosing	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual
Typical duration	10-30 day cycles	10-30 day cycles
Administration	Oral capsules or sublingual	Oral capsules or sublingual
Timing	Morning on an empty stomach Take on an empty stomach	Morning on an empty stomach Take on an empty stomach
Evidence level	Preclinical	Preclinical
Possible side effects	Generally well tolerated (Reported by the source; detailed safety data are limited.) Limited safety data outside Russia (The source flags this as a limitation of the available safety evidence.) Not FDA approved (This is regulatory status rather than a physiological adverse effect.)	Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.) Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.) Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)
Research summary	The supplied source characterizes the published evidence as mainly in vitro and ex vivo. It notes work on EDP-class peptides in PHA-stimulated lymphocytes from elderly donors, including reported chromatin-structure changes, and mentions lymphocyte activity findings in thymic explant and epithelial-cell models. A Russian clinical-observational report is described as commonly cited, but the source says it was not a registered randomized trial, so human efficacy should be treated as preliminary.	The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.
References	PubMed PMC +1 more International Journal of Molecular SciencesTransport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Crystagen

Chonluten

Category

Bioregulators

Also known as

Glu-Asp-Pro, EDP

Glu-Asp-Gly, EDG

FDA approved

Clinical status

Preclinical research; reported as supplement-approved in Russia

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical research; reported supplement approval in Russia; not FDA or EMA approved

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Immune system, spleen health, immune aging

Respiratory health, lung function, bronchial support

How it works

Crystagen is presented as a cytogen-class short peptide. In the supplied source, the Khavinson group hypothesizes that EDP can influence lymphocyte proliferation and differentiation and may reactivate chromatin in aged immune cells, potentially relating to T-cell function through tissue-specific gene-expression regulation. The source explicitly treats this as a proposed epigenetic model supported by that group's in vitro work, not as independent scientific consensus.

Chonluten is presented under the Khavinson bioregulator framework, where short peptides are proposed to enter cells and influence nuclear gene-expression activity. For Chonluten specifically, the source links the hypothesis to respiratory epithelial tissue and genes related to stress response, antioxidant activity, and inflammation. The same evidence cautions that this remains a proposed mechanism, with uncertainty about whether free EDG reaches human nuclei at relevant concentrations or binds specific DNA regions in a clinically meaningful way.

Typical dosing

10-20 mg daily · Once or twice daily

Research dosing

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

Typical duration

10-30 day cycles

Administration

Oral capsules or sublingual

Timing

Morning on an empty stomach

Take on an empty stomach

Morning on an empty stomach

Take on an empty stomach

Evidence level

Preclinical

Possible side effects

Generally well tolerated (Reported by the source; detailed safety data are limited.)
Limited safety data outside Russia (The source flags this as a limitation of the available safety evidence.)
Not FDA approved (This is regulatory status rather than a physiological adverse effect.)

Generally well tolerated in the source report (The source does not provide detailed adverse-event rates or controlled safety data.)
Limited safety data outside Russia (Safety generalizability is uncertain because the source highlights limited data beyond Russian research settings.)
Not FDA approved (Regulatory non-approval is safety context, not a specific adverse effect.)

Research summary

The supplied source characterizes the published evidence as mainly in vitro and ex vivo. It notes work on EDP-class peptides in PHA-stimulated lymphocytes from elderly donors, including reported chromatin-structure changes, and mentions lymphocyte activity findings in thymic explant and epithelial-cell models. A Russian clinical-observational report is described as commonly cited, but the source says it was not a registered randomized trial, so human efficacy should be treated as preliminary.

The supplied source connects Chonluten, the EDG tripeptide, to Khavinson-group work on bronchopulmonary tissue. It reports discussion of oral EDG in chronic bronchitis with an asthmatic component and mentions related work pairing EDG with Bronchogen in chronic obstructive pulmonary disease contexts. The evidence base is described as concentrated in one research network, with uncontrolled clinical observations, limited independent replication, no registered randomized controlled trials, and mechanistic claims relying on cell-culture or animal findings rather than confirmed human outcomes.

References

PubMed PMC

+1 more

International Journal of Molecular SciencesTransport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers

Source Source

+2 more

Source Source

Full profile

View Details